mitochondrial biogenesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
=== Specialized === Laboratory tests (e.g. Erythrocyte Sedimentation Rate, Rheumatoid Factor, Anti-CCP (Anti-citrullinated protein antibody), ANA (Anti-Nuclear Antibody) ) X-rays, Ultrasounds, and other imaging methods of affected joints Cytopathology and chemical pathology of fluid aspirated from affected joints (e.g. to differentiate between septic arthritis and gout)
=== Sterilization of biomedical materials === Supercritical CO2 is an alternative for thermal sterilization of biological materials and medical devices with combination of the additive peracetic acid (PAA). Supercritical CO2 does not sterilize the media, because it does not kill the spores of microorganisms. Moreover, this process is gentle, as the morphology, ultrastructure and protein profiles of inactivated microbes are preserved.
== Plot == The future United States is a dystopic irradiated wasteland known as the Cursed Earth. On the east coast lies Mega-City One, a violent metropolis with 800 million residents and 17,000 serious crimes reported daily. The only force for order are the Judges, who act as judge, jury, and executioner. The Chief Judge tasks veteran officer Judge Dredd with assessing potential recruit Cassandra Anderson, who marginally failed the aptitude tests to become a Judge, believing her powerful psychic abilities can help in the Judges' failing war against crime. Dredd warns Anderson that disobedience, incorrect sentencing, or being disarmed will result in an automatic fail. In a 200-storey slum tower block called Peach Trees, drug lord Madeline "Ma-Ma" Madrigal has three rogue drug dealers skinned and infused with Slo-Mo—an addictive new drug that reduces the user's perception of time to 1% of normal—before throwing them down the atrium from the top floor. Dredd and Anderson arrive to investigate the deaths and learn of the existence of Ma-Ma's drug den. Deciding to raid the den, they arrest Ma-Ma's henchman Kay, who Anderson psychically detects was involved in the executions, and Dredd decides to take him in for questioning. In response, Ma-Ma's forces seize the tower's security control room and seal the building using its nuclear blast shields to prevent the Judges from leaving or summoning help. Ma-Ma instructs the residents to kill the Judges or hide, forcing Dredd and Anderson to confront dozens of armed thugs.
Other uses include determining high-precision values for plutonium and uranium isotopes in a rapid fashion, investigating the atomic properties of technetium at the ultra trace level, and capturing the concurrent excitation of stable daughter atoms with the decay of their parent atoms as is the case for alpha particles, beta rays, and positrons. RIS is now in very common use in research facilities where the quick and quantitative determination of the elemental composition of materials is important. Pulsed laser light sources provide higher photon fluxes than continuous-wave lasers do, however the use of pulsed lasers currently limit vast applications of RIMS in two ways. One, photo ions are created only during short laser pulses, thus significantly reducing the duty cycle of pulsed resonance ionization mass spectrometers relative to their continuous-beam counterparts. Two, incessant drifts in laser pointing and pulse timing alongside jitters between pulses severely hamper chances of reproducibility. These issues affect the extent to which resonance ionization can be used to solve some of the challenges confronted by practical analysts today; even so, applications of RIMS are replete in various traditional and emerging disciplines such as cosmochemistry, medical research, environmental chemistry, geophysical sciences, nuclear physics, genome sequencing, and semiconductors.
PfSPZ Vaccine is a metabolically active non-replicating whole sporozoite (SPZ) malaria vaccine being developed by Sanaria against Plasmodium falciparum (Pf) malaria. Clinical trials have been safe, extremely well tolerated and highly efficacious. The first generation PfSPZ product is attenuated by gamma irradiation; the second generation vaccines PfSPZ-CVac and PfSPZ LARC2 are, respectively, attenuated chemically and genetically. Multiple studies are ongoing with trials of the PfSPZ vaccines. All three products are produced using the same manufacturing process. These products are stored and distributed below -150 °C using liquid nitrogen (LN2) vapor phase (LNVP) freezers and cryoshippers.
Sources: en.wikipedia.org
=== Quality, digestibility and energy density === There are a few key components to consider when evaluating dietary needs. These factors include the quality and digestibility of the protein provided in the diet, as well as the composition of the amino acids included, and finally the energy density provided in the diet. Diets containing proteins that are high in quality, composition, and digestibility require less of that protein to be present. The same can be said in regards to the energy density. In contrast, high-protein diets will provide excess protein content after meeting maintenance demands; this can therefore lead to the protein being utilized in fat and energy storage. This ultimately increases the risk for developing obesity and other health related issues. Higher protein in the diet helps reduce lean body mass loss, but will not lead to an increase in size of muscle unless paired with resistance exercises or anabolic steroids under maintenance conditions.
== Research == Medical authorities generally recommend obtaining beta-carotene from food rather than dietary supplements. A 2013 meta-analysis of randomized controlled trials concluded that high-dosage (≥9.6 mg/day) beta-carotene supplementation is associated with a 6% increase in the risk of all-cause mortality, while low-dosage (<9.6 mg/day) supplementation does not have a significant effect on mortality. Research is insufficient to determine whether a minimum level of beta-carotene consumption is necessary for human health and to identify what problems might arise from insufficient beta-carotene intake. However, a 2018 meta-analysis mostly of prospective cohort studies found that both dietary and circulating beta-carotene are associated with a lower risk of all-cause mortality. The highest circulating beta-carotene category, compared to the lowest, correlated with a 37% reduction in the risk of all-cause mortality, while the highest dietary beta-carotene intake category, compared to the lowest, was linked to an 18% decrease in the risk of all-cause mortality.
== Professional ventures and affiliations == Early in his career, Ariely co-founded the behavioral economics consulting firm BEworks, which was acquired by Kyu in 2017. In 2012, aspiring to develop a time management app that helps people "use time better" and avoid procrastination, Ariely co-founded Timeful with Yoav Shoham and Jacob Bank. The app was acquired by Google in 2015. In 2013, Ariely and Kristen Berman co-founded Irrational Labs, a consulting firm aimed at applying behavioral economics to consumer behavior and decision-making. In 2014, Ariely co-founded the kitchen appliance company Genie with Ayelet Carasso-Stenberg and Doron Marco. Genie manufactures a food "replicator" that cooks freeze-dried meals in cartridges. In 2015, Ariely invested in Qapital, a personal finance app, and was appointed as its chief behavioral economist. He was later named chair of the board. In 2015, Ariely gave a talk at Google about dating and relationships, discussing what women want from men, including how women's attraction to men varies depending where they are in their menstrual cycle. This was one of many talks Ariely collaborated with Google on over several years, including, for example, a talk about how people rationalize cheating. In 2016, he took on the position of chief behavioral officer at Lemonade, an insurance company that integrates aspects of behavioral economics into its insurance model. Ariely's entrepreneurial ventures also include founding Shapa in 2017, a company focused on health monitoring and behavior change.
Chromatographic methods with fluorescence detection Liquid chromatography with fluorescence detection (LC-FLD) provides a selective, relatively cheap, reproducible method for the qualitative and quantitative analysis of YTX for shellfish and algae samples. This method requires an additional sample preparation step after the analyte extraction procedure has been completed (in this case SPE is preferentially used so common interferences can be removed from the sample). This additional step involves the derivatization of the YTXs with a fluorescent dienophile reagent — dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl]-1,2,4-triazoline-3,5-dione, which facilitates analyte detection. This additional sample preparation step can make LC-FLD analysis extremely time-consuming and is a major disadvantage of the technique.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.